Athira Pharma, Inc.
Industry
- Biotechnology
- Drug Discovery Technologies
- Pharmaceuticals
- Vaccines
Other Names/Subsidiaries
- M3 Biotechnology
Latest on Athira Pharma, Inc.
Biopharmaceutical companies celebrated recent positive data readouts with a slew of significant follow-on public offerings (FOPOs), including Nuvalent, Inc. , which grossed $500m on 16 September from
Topline results from the Phase II/III LIFT-AD clinical trial of Athira Pharma, Inc. ’s hepatocyte growth factor (HGF) modulator fosgonimeton in mild-to-moderate Alzheimer’s disease show the drug did
“We’ve seen some tremendous acceleration in science over the past few years and that science is the driving force behind new medicines. The fundamental need for these new medicines is the underpinning
Privately held biotech Defender Pharmaceuticals ’ lead candidate, DPI-386, has met the primary endpoint in a Phase III motion sickness trial, sparking plans for a new drug application as the firm sim